ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,958.35
1.56%
US Tech 100
20,868.40
1.47%
Dow Jones
43,029.60
1.62%
Brent Oil
72.955
0.79%
Bitcoin
97,155.69
-0.31%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. USOTC

  6. Vivos Inc (QB) (RDGL) Quote

Vivos Inc (QB)

Vivos Inc (QB) (RDGL)

USOTC
0.08465
0.00465
( 5.81% )
Updated: 13:38:57
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.08465
Bid
0.0835
Ask
0.0875
Volume
361,948
0.082 Day's Range 0.0878
0.049 52 Week Range 0.255
Market Cap
35.349M
Previous Close
0.08
Open
0.082
Last Trade
2405
@
0.08465
Last Trade Time
13:17:02
Financial Volume
$ 30,691
VWAP
0.084794
Average Volume (3m)
1,035,969
Shares Outstanding
417,592,703
Dividend Yield
-
PE Ratio
-13.04
Earnings Per Share (EPS)
-0.01
Revenue
20k
Net Profit
-2.9M

About Vivos Inc (QB)

Vivos Inc, developed an yttrium-90 brachytherapy device to combat cancer in humans and animals. Testing at Washington State University, the University of Missouri and our pilot veterinary clinic has verified the safety to the patient, the therapist and the family members. IsoPet is commercially avai... Vivos Inc, developed an yttrium-90 brachytherapy device to combat cancer in humans and animals. Testing at Washington State University, the University of Missouri and our pilot veterinary clinic has verified the safety to the patient, the therapist and the family members. IsoPet is commercially available for animal therapy and can deliver very high doses to solid tumors with a single same day therapy. Pre-clinical testing is in progress to generate key data for an Investigational Devise Exemption to the FDA to begin human clinical trials. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
www.radiogel.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Vivos Inc (QB) is listed in the Surgical,med Instr,apparatus sector of the OTCMarkets with ticker RDGL. The last closing price for Vivos (QB) was $0.08. Over the last year, Vivos (QB) shares have traded in a share price range of $ 0.049 to $ 0.255.

Vivos (QB) currently has 417,592,703 shares outstanding. The market capitalization of Vivos (QB) is $33.41 million. Vivos (QB) has a price to earnings ratio (PE ratio) of -13.04.

Ask ADVFN Intelligence (AI)

RDGL Latest News

More News

Form 253G2 -

November 18 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 13 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

October 28 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

September 30 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

August 13 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 13 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

August 07 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

August 02 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

July 29 2024
Edgar (US Regulatory)

Form QUALIF - Notice of Qualification [Regulation A]

July 17 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.003654.506172839510.0810.08780.061113111010.07601373CS
4-0.00385-4.350282485880.08850.0970.061110577030.08243293CS
12-0.08235-49.31137724550.1670.180.061110359690.11076432CS
26-0.13385-61.25858123570.21850.2550.061113568240.13360025CS
520.0321561.23809523810.05250.2550.04912738480.13160798CS
1560.0095512.71637816250.07510.2550.047522430.10224444CS
2600.0449112.9559748430.039750.310.013510699470.10147462CS

RDGL - Frequently Asked Questions (FAQ)

What is the current Vivos (QB) share price?
The current share price of Vivos (QB) is $ 0.08465
How many Vivos (QB) shares are in issue?
Vivos (QB) has 417,592,703 shares in issue
What is the market cap of Vivos (QB)?
The market capitalisation of Vivos (QB) is USD 33.41M
What is the 1 year trading range for Vivos (QB) share price?
Vivos (QB) has traded in the range of $ 0.049 to $ 0.255 during the past year
What is the PE ratio of Vivos (QB)?
The price to earnings ratio of Vivos (QB) is -13.04
What is the reporting currency for Vivos (QB)?
Vivos (QB) reports financial results in USD
What is the latest annual turnover for Vivos (QB)?
The latest annual turnover of Vivos (QB) is USD 20k
What is the latest annual profit for Vivos (QB)?
The latest annual profit of Vivos (QB) is USD -2.9M
What is the registered address of Vivos (QB)?
The registered address for Vivos (QB) is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Vivos (QB) website address?
The website address for Vivos (QB) is www.radiogel.com
Which industry sector does Vivos (QB) operate in?
Vivos (QB) operates in the SURGICAL,MED INSTR,APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ELIQQElectriq Power Holdings Inc (CE)
$ 0.10
(99,900.00%)
100
GNTLFGenetic Technologies Ltd (PK)
$ 1.00
(90,809.09%)
100
VIVEViveve Medical Inc (CE)
$ 0.0003
(29,900.00%)
7.33k
BTIMBoatim Inc (CE)
$ 0.0002
(19,900.00%)
799
CLVRClever Leaves Holdings Inc (CE)
$ 0.0002
(19,900.00%)
590
RAASYCloopen Group Holding Limited (CE)
$ 0.000001
(-100.00%)
204
EWGFFEat Well Investment Group Inc (CE)
$ 0.000001
(-100.00%)
47.01k
AGDXFAntioqua Gold Inc (CE)
$ 0.000001
(-99.99%)
102k
SOLBFSoLVBL Solutions Inc (CE)
$ 0.000001
(-99.99%)
10k
NMRDNemaura Medical Inc (CE)
$ 0.000001
(-99.50%)
3.6k
HMBLHUMBL Inc (PK)
$ 0.0009
(0.00%)
302.39M
PHILPHI Group Inc (PK)
$ 0.0003
(0.00%)
230.4M
PLPLPlandai Biotechnology Inc (PK)
$ 0.0001
(0.00%)
215.58M
RDARRaadr Inc (PK)
$ 0.0014
(16.67%)
117.3M
CHNVFChina Youzan Ltd (PK)
$ 0.0177
(10.63%)
100M

RDGL Discussion

View Posts
konshe konshe 3 hours ago
This oversold and undervalued stock now is going up. Uptrend is confirmed. Next week it will break out 0.10 for sure. RDGL is a best stock to own on 2025.
👍 3
FatFatCat FatFatCat 3 hours ago
Nice volume this morning.

To those arguing with idiots, remember this:

“Never argue with an idiot. They will drag you down to their level and beat you with experience.”
-- Mark Twain
👍 3
chereb19 chereb19 3 hours ago
Your inability to say they lied in a SEC filing tells us all we need to know.

You must love the Doc and be proud he managed to get a BDD
👍️0
Truthsocial Truthsocial 4 hours ago
Is your garbage company doing as well as these garbage companies....asking for RDGL CEO Dr Korenko

https://www.zippia.com/advice/largest-waste-management-companies/
👍️0
SC8 SC8 4 hours ago
The only source for the BDD claim is MK,, a proven serial liar. But it doesn't matter now whether true or not. Time has proven the "news" was of no consequence towards getting Radiogel to market.
👍️0
Rum_Tequila Rum_Tequila 4 hours ago
it must be so gratifying for you to make a (paltry) living attempting to dupe the most low IQ of investors with your idiotic claims… no independent verification? it was NEWS
👍️0
chereb19 chereb19 4 hours ago
It's on there SEC filings.

You won't say they are lying there so one can only conclude you believe it's been granted.
👍️0
chereb19 chereb19 4 hours ago
Not my fault you can't read a 10-q

Isopet is profitable.
👍️0
SC8 SC8 4 hours ago
If FDA awarded BDD to Radiogel (there's been no independent corroboration to serial liar MK's claim), it's year old news now and has proven to be of no consequence. To date MK hasn't even bothered to ask FDA for human trial authorization. They told him years ago what they need and he either can't or won't deliver. Those are the known facts.
👍️0
SC8 SC8 5 hours ago
Sorry, but there is no plausible scenario of RDGL surviving without getting Radiogel to market. Every $ and every minute that MK spends on hopeless IsoPet is a $ and a minute robbed from the only thing that matters. It's just another example of his gross incompetence.
👍️0
Truthsocial Truthsocial 6 hours ago
You really should invest in a garbage company because alone you would be their biggest customer without a doubt...

Expansion of many more veterinarian locations treatments with Isopet can be very profitable everyone knows this except Elmer's glue stick...
And do you really believe these veterinarians are paying attention to
Mr Elmer's glue stick lol
No they have done their due diligence I'm sure.
Wow what a loser Elmer Fudd is
Many companies also operate at a loss on paper but are valued in the billions.
Not Sounding to intelligent just a useless distraction skat....

RDGL MAYO CLINIC AND ISOPET LEADING THE WAY

To eliminate cancer with outpatient treatment

On another note
👍️0
chereb19 chereb19 6 hours ago
The SEC filings don't lie. Isopet made a profit.

Isopet and Radiogel are in a class of their own. They have a breakthrough device designation from the FDA proving they have no competition.
👍️0
chereb19 chereb19 6 hours ago
Whopper of a lie
You really can't be trusted
👍️0
SC8 SC8 6 hours ago
RDGL's financials say otherwise. Most IsoPet treatments are sold at a loss. There is no plausible scenario of RDGL becoming profitable via IsoPet no matter how long MK extends runway via dilution. IsoPet is a sad distraction for what now? 6 years?
👍️0
SC8 SC8 6 hours ago
Already asked and answered. Read the quarterly financials. It's all there. Most if not all IsoPet treatments are sold at a loss. Many one can cherry pick some profitable IsoPet treatments but there's no plausible scenario of RDGL even getting close to covering their overhead via IsoPet treatments no matter how long someone extends the runway via dilution. Those facts are what makes IsoPet a hopeless distraction being done at the expense of only thing that matters: getting Radiogel to market.

RDGL is an FDA play, nothing more, and MK has proven completely incompetent dealing with FDA.
👍️0
chereb19 chereb19 8 hours ago
Read the last 10-Q
👍️0
rogers711 rogers711 8 hours ago
That's also not true... 😂 where? 
👍️0
chereb19 chereb19 11 hours ago
Isopet has been proven to be profitable
👍️0
rickstereo3333 rickstereo3333 15 hours ago
Could someone kindly create a "GLUE" Board so this Muppet eejit can saunter over and debate himself..........SC8sceeate???

TIA
👍 1
rickstereo3333 rickstereo3333 15 hours ago
All pointless if it fails and based on what i've seen.......its sticky shite!
👍 1
Shanesland Shanesland 17 hours ago
Complete idiot... Nobody here wants the glue….
👍️ 2
rogers711 rogers711 18 hours ago
Nobody was talking about overhead... isopet, you claim you know they are selling it for a loss... how?
👍️ 1
SC8 SC8 19 hours ago
RDGL overhead is at minimum ~$2.5 million/year. That's what they need from IsoPet just to break even. Even if IsoPet was profitable, there's no plausible path to get the needed volume. But so far IsoPet isn't profitable. Most all IsoPet treatments are sold below cost. The situation is hopeless. Only thing that matters now is getting Radiogel to market and MK has proven completely incapable of doing so.
👍️0
WhAtEvA1 WhAtEvA1 19 hours ago
Poor 👉AtlasQ and mc73 salivating for 0.05, LOL!
👍️0
SC8 SC8 19 hours ago
Just look are last couple years or more of RDGL quarterly financials. IsoPet is a hopeless distraction.
👍️0
SC8 SC8 19 hours ago
If Doc Fisher is so great, why did he set back RDGL many years by failing to verify Radiogel containment in rabbit tumors within the critical 10 day period after treatment? He screwed up so bad the work had to be repeated at JHU Vet School. Doc Fisher is just another gross incompetent.
👍️0
rogers711 rogers711 19 hours ago
That's not how profit works bud 😂😂 it's impossible to break even and profit 2.5 million 
👍️0
SC8 SC8 19 hours ago
So why isn't IsoPet even close to making RDGL profitable? It was launched what, 6 years ago? Why did it never take off, even when sold below cost? IsoPet is hopelessly unprofitable. Facts are facts
👍️0
SC8 SC8 20 hours ago
Read the financials. Most all IsoPet treatments are sold below cost. Moreover, IsoPet would have to yield $2.5 million/year just for RDGL to break even. That's not $2.5 million in revenue, but $2.5 million in profit just for RDGL to break even. There is no plausible path for RDGL to become profitable via IsoPet. It's just a sad distraction that MK is running at the expense of only thing that can save RDGL: getting Radiogel to market. To date, MK hasn't even bothered to ask FDA for authorization for human trials. He failed to get Radiogel to market before the original patents expired. In the meantime RDGL's competition has moved ahead into clinical trials.

Not my fault MK is a gross incompetent. Situation is what it is. I just cite the facts and draw obvious conclusions.
👍️0
konshe konshe 22 hours ago
RDGL great green chart, buy buy buy,run run run 2025 best stock.

https://www.stockscores.com/charts/charts/?ticker=rdgl
👍️0
rogers711 rogers711 1 day ago
Can you provide where cost vs profit is on isopet? I haven't found that info. 
👍️0
doccjc doccjc 1 day ago
Many care what the competent Dr Fisher thinks.
I'd listen more to what Dr Fisher has to say over someone pumping a glue company on a public message board.
Facts are facts and the lights will be coming on soon enough.
👍️ 1
Bigfootbud Bigfootbud 1 day ago
The global veterinary oncology market size was estimated at USD 1.57 billion in 2024 and is projected to grow at a CAGR of 12.08% from 2025 to 2030. Key growth drivers include increasing the prevalence of cancer in pets, increasing R&D in pet cancer therapy, and growing focus on animal safety. As per The Veterinary Cancer Society, cancer is the top reason of death in 47% of canines, particularly those over 10 years old, and in 32% of felines. In addition, around 1 in 4 dogs will experience abnormal tissue growth or neoplasia during their lifetime.

https://www.grandviewresearch.com/industry-analysis/veterinary-oncology-market
👍️ 1
Elonlies Elonlies 1 day ago
I strongly disagree SC8

Dr. Korenko is a very competent and RDGL has a bright future. Many lives will be saved!! The best is yet to come. GO RDGL!!
👍️0
Truthsocial Truthsocial 1 day ago
Prove your lies .....please without schuitt

When the ISOPET and RDGL treatments start increasing in volume they will easily become profitable this outpatient treatment is just beginning to become more mainstream watch and listen ...
Beginning of the new year announcements will prove you a fake...
Many more veterinarians coming on board
Then we have worldwide human clinical trials beginning imo
Try pounding sand with your d....
GO pedal your gluestick elsewhere
👍️0
1hunglo 1hunglo 1 day ago
I wholeheartedly believe in the Science but not the Scientist > No GO Korenko.
RDGL desperately needs a new capable CEO. In anyones intelligent opinion of the facts.
ANOTHER YEAR WASTED BY NGK & HIS HUGE EGO. SO SAD.
WHEN THERE ARE MANY LIVES THAT COULD HAVE BEEN SAVED IN THE PAST YEARS.
👍️ 1
chereb19 chereb19 1 day ago
What a whopper of a lie

https://isopet.com/
👍️0
SC8 SC8 1 day ago
Doesn't matter if there's demand for IsoPet or not when it's sold below cost. IsoPet would have to yield at least $2.5 million profit just for RDGL to break even. There's no plausible path to get there. It's a distraction. RDGL is an FDA play, nothing more, and MK has proven inept dealing with FDA.
👍️0
chereb19 chereb19 1 day ago
Still can't bring yourself to say they lied in SEC filings. Point is, your continued silence is an endorsement for the doc and Vivos

24/7
👍️0
SC8 SC8 1 day ago
Not my job to parse MK's lies from truth. Just saying MK is a confirmed serial liar and no reasonable person should believe anything he says. Regarding BDD, the point is moot either way. It's year old news now and has had no impact getting Radiogel to human trials.
👍️0
AtlasQ AtlasQ 1 day ago
Please humor me and tell me what did you figure out about me. 
👍️0
SC8 SC8 1 day ago
IsoPet has no plausible path to profitability. It's been a distraction for years done at expense of getting Radiogel to market. Just another example of MK's gross incompetence.
👍️0
SC8 SC8 1 day ago
Who cares what incompetent Dr. Fisher thinks (the guy who failed to do PET scans on rabbits within the critical ten days after Radiogel application to verify containment). He's the reason the rabbit testing had to be repeated by competent people at JHU Vet school!

Fact is YntraDose is in clinical trials and Radiogel isn't. Incompetent Dr. Fisher's opinion doesn't change that fact.

Facts are facts.
👍️ 1
rogers711 rogers711 1 day ago
If you are spending money expanding something not in demand it could be...
👍️0
lovethatgreen lovethatgreen 1 day ago
Don't need to be to figure you out
👍️0
lovethatgreen lovethatgreen 1 day ago
You've been a flip flop idiot right from the get go
👍️0
Truthsocial Truthsocial 1 day ago
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175547124
👍️0
chereb19 chereb19 2 days ago
Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program.

👍️0
chereb19 chereb19 2 days ago
Still can't bring yourself to say they lied in SEC filings. Point is, your continued silence is an endorsement for the doc and Vivos

24/7

👍️0
Bigfootbud Bigfootbud 2 days ago
expansion is not a negative. ♥
👍️0

Your Recent History

USOTC
RDGL
Vivos (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads